[go: up one dir, main page]

DE69829112D1 - Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom - Google Patents

Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom

Info

Publication number
DE69829112D1
DE69829112D1 DE69829112T DE69829112T DE69829112D1 DE 69829112 D1 DE69829112 D1 DE 69829112D1 DE 69829112 T DE69829112 T DE 69829112T DE 69829112 T DE69829112 T DE 69829112T DE 69829112 D1 DE69829112 D1 DE 69829112D1
Authority
DE
Germany
Prior art keywords
fibromyalgia
treatment
butyrate derivatives
syndrome
chronic tired
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69829112T
Other languages
English (en)
Other versions
DE69829112T2 (de
Inventor
B Scharf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orphan Medical Inc
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Application granted granted Critical
Publication of DE69829112D1 publication Critical patent/DE69829112D1/de
Publication of DE69829112T2 publication Critical patent/DE69829112T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69829112T 1997-08-29 1998-08-27 Butyrate Derivate zur Behandlung von Fibromyalgia und chronischem Müdigkeits-Syndrom Expired - Fee Related DE69829112T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US920979 1997-08-29
US08/920,979 US5990162A (en) 1997-08-29 1997-08-29 Method for treatment of fibromyalgia and chronic fatigue syndrome
PCT/US1998/017818 WO1999009972A1 (en) 1997-08-29 1998-08-27 Butyrate derivatives in the treatment of fibromyalgia and chronic fatigue syndrome

Publications (2)

Publication Number Publication Date
DE69829112D1 true DE69829112D1 (de) 2005-03-31
DE69829112T2 DE69829112T2 (de) 2005-08-25

Family

ID=25444733

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69829112T Expired - Fee Related DE69829112T2 (de) 1997-08-29 1998-08-27 Butyrate Derivate zur Behandlung von Fibromyalgia und chronischem Müdigkeits-Syndrom

Country Status (15)

Country Link
US (1) US5990162A (de)
EP (1) EP1017381B1 (de)
JP (1) JP3660587B2 (de)
AT (1) ATE289508T1 (de)
AU (1) AU737086B2 (de)
CA (1) CA2301723C (de)
CZ (1) CZ295248B6 (de)
DE (1) DE69829112T2 (de)
ES (1) ES2235355T3 (de)
HK (1) HK1029278A1 (de)
IL (2) IL134669A0 (de)
NO (1) NO326479B1 (de)
NZ (1) NZ502983A (de)
PT (1) PT1017381E (de)
WO (1) WO1999009972A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU779354B2 (en) * 1998-12-23 2005-01-20 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
EP1316309A1 (de) * 1998-12-23 2003-06-04 Orphan Medical Inc. Mikrobenbeständige und stabilisierte Lösungen die gamma-Hydroxybuttersäuresalze zur Behandlung von Narkolepsie enthalten
EP1163019B1 (de) 1999-03-25 2007-10-24 Metabolix, Inc. Medizinische vorrichtungen und verwendungen von polyhydroxyalkanoatpolymeren
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
US6623730B1 (en) * 1999-09-14 2003-09-23 Tepha, Inc. Therapeutic uses of polymers and oligomers comprising gamma-hydroxybutyrate
AU2001291173A1 (en) 2000-09-22 2002-04-02 Orphan Medical, Inc. Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers
US7553829B2 (en) * 2000-11-30 2009-06-30 Humanetics Corporation Treatment of chronic fatigue syndrome and fibromyalgia syndrome
JP2005510482A (ja) * 2001-10-16 2005-04-21 アストラゼネカ・アクチエボラーグ 線維筋痛症候群の治療方法
US6703216B2 (en) 2002-03-14 2004-03-09 The Regents Of The University Of California Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid (GHB)
AU2004238229B2 (en) 2003-05-08 2007-07-12 Tepha, Inc. Polyhydroxyalkanoate medical textiles and fibers
DE602005022197D1 (de) 2004-08-03 2010-08-19 Tepha Inc Nichtkräuselnde polyhydroxyalkanoatnähte
JP2008512386A (ja) * 2004-09-07 2008-04-24 オーファン メディカル，インコーポレイティド 改良型ｇｈｂ組成物
AU2005304352A1 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Method for treatment of movement disorders
WO2006124609A2 (en) * 2005-05-16 2006-11-23 Joseph Johnson Methods and compositions for treating arg
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
US7943683B2 (en) 2006-12-01 2011-05-17 Tepha, Inc. Medical devices containing oriented films of poly-4-hydroxybutyrate and copolymers
EP2240239A4 (de) * 2008-01-30 2013-11-27 Great Lakes Biosciences Llc Verfahren und vorrichtung zur behandlung von hirnspezifischem chronischem schmerz
CA2740029C (en) * 2008-05-16 2016-12-20 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
EP2421808B1 (en) 2009-04-23 2013-07-31 Concert Pharmaceuticals Inc. 4-hydroxybutyric acid analogs
MX377251B (es) 2010-03-24 2025-03-07 Jazz Pharmaceuticals Inc Star Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
CA2732479A1 (en) * 2011-02-14 2012-08-14 Concert Pharmaceuticals, Inc. 4-hydroxybutyric acid analogs
KR101976218B1 (ko) * 2011-02-14 2019-05-07 콘서트 파마슈티컬즈, 인크. 4-히드록시부티르산 중수소화 유사체
WO2014078014A2 (en) 2012-11-14 2014-05-22 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
US8591922B1 (en) 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
EP3180040B1 (de) 2014-08-15 2020-05-13 Tepha, Inc. Selbsthaltendes chirurgisches nahtmaterial aus poly-4-hydroxybutyrat und copolymeren davon
EP3230500A1 (de) 2014-12-11 2017-10-18 Tepha, Inc. Verfahren zur ausrichtung von multifilamentgarn und monofilamenten aus poly-4-hydroxybutyrat und copolymere davon
US10626521B2 (en) 2014-12-11 2020-04-21 Tepha, Inc. Methods of manufacturing mesh sutures from poly-4-hydroxybutyrate and copolymers thereof
WO2016102407A1 (en) 2014-12-22 2016-06-30 Sanofi-Aventis Deutschland Gmbh Drug delivery device with electromagnetic drive unit
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
FR3049463B1 (fr) 2016-04-01 2019-07-05 Debregeas Et Associes Pharma Doses unitaires a liberation immediate de ghb ou de l'un de ses sels therapeutiquement acceptables administrees par voie orale et leur utilisation pour maintenir l'abstinence alcoolique
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3737353A1 (de) 2017-12-18 2020-11-18 Tris Pharma, Inc. Pharmazeutische ghb-zusammensetzungen mit einem system zur formung von schwimmenden interpenetrierenden polymernetzwerken
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
JP2021506984A (ja) 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型ｒａｆｔ形成システムを含む放出調節薬物粉末組成物
BR112021006027A2 (pt) 2018-11-19 2021-06-29 Jazz Pharmaceuticals Ireland Limited formulações de fármaco resistente a álcool
US11400065B2 (en) 2019-03-01 2022-08-02 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
EP4228620A2 (de) 2020-10-16 2023-08-23 Jazz Pharmaceuticals Ireland Limited Behandlungsverfahren mit ghb
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60168044A (ja) * 1984-02-10 1985-08-31 Sharp Corp 感湿素子
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
JPH05262654A (ja) * 1992-03-18 1993-10-12 Kaken Pharmaceut Co Ltd 慢性疲労症候群治療剤
ITTO930510A1 (it) * 1993-07-09 1993-10-07 Walter Tarello Farmaci attivi contro la chronic fatigue syndrome (c.f.s.)
IT1266565B1 (it) * 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin

Also Published As

Publication number Publication date
EP1017381B1 (de) 2005-02-23
CA2301723C (en) 2008-02-19
EP1017381A1 (de) 2000-07-12
AU737086B2 (en) 2001-08-09
DE69829112T2 (de) 2005-08-25
CA2301723A1 (en) 1999-03-04
IL134669A0 (en) 2001-04-30
ES2235355T3 (es) 2005-07-01
IL134669A (en) 2006-08-20
AU8923798A (en) 1999-03-16
NO326479B1 (no) 2008-12-15
WO1999009972A1 (en) 1999-03-04
JP3660587B2 (ja) 2005-06-15
US5990162A (en) 1999-11-23
PT1017381E (pt) 2005-06-30
CZ295248B6 (cs) 2005-06-15
NZ502983A (en) 2001-08-31
HK1029278A1 (en) 2001-03-30
CZ2000741A3 (cs) 2000-09-13
NO20000989L (no) 2000-04-03
ATE289508T1 (de) 2005-03-15
NO20000989D0 (no) 2000-02-28
JP2001513552A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
DE69829112D1 (de) Butyrate derivaten zur behandlung von fibromyalgia und chronische müdigkeit-syndrom
PT934061E (pt) Isobutilgaba e seus derivados para o tratamento da dor
ATE461698T1 (de) Gaba-analoga zur verhütung und behandlung gastrointestinaler beschwerden
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE58902094D1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
DE69703689D1 (de) Therapeutische anwendungen von bpi-protein-produkten zur behandlung von humaner meningococcämia
ATE238047T1 (de) Verwendung von n,n-bis (phenylcarbamoylmethyl) dimethylammoniumchlorid und derivaten davon zur behandlung von chronischem schmerz
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
EE9700302A (et) Meetod maania ja bipolaarse häire raviks
EP1043983A4 (de) Tetracycline und/oder tetracyclinderivate zur behandlung und prophylaxe von cerebrovascularen krankheiten des nervensystems
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
ES2058349T3 (es) Utilizacion de betabloqueadores para el tratamiento de la progresion de la miopia axial infantil.
BR9612552A (pt) Processo para tratamento de autismo
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
DE68909750D1 (de) Vorrichtung zur therapeutischen behandlung von lumbago sowie lumbago/ischias.
ATE295731T1 (de) Olanzapine zur behandlung von drogenmissbrauch
NO984198L (no) FremgangsmÕte for behandling av aggresjon
ATE225181T1 (de) Verwendung von heparinen niedrigeren molekulargewichtes zur behandlung von hirnödemen
ES2181786T3 (es) Putamen ovi
ES2141923T3 (es) Uso hipocolesterolemico, antiaterosclerotico e hipotrigliceridemico de derivados aminoacetilmercapto.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee